Mouse model of hepatocellular hyperplastic nodule formation characterization of mRNA expression

Hepatology Research

Volumn 15, Issue 2, 1999, Pages 110-123

  Nagao, Yasuyuki ^a   Wan, Yu Jui Y ^c   Yuan, Qi X ^c   Kachi, Kazutomo ^a   Marceau, Norman ^b   French, Samuel W ^c  

^a KYOTO PREFECTURAL UNIVERSITY   (Japan)

^b UNIVERSITÉ LAVAL   (Canada)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Glutamyl transpeptidase; c Jun; c Myc; CK8; Griseofulvin; Hepatocellular carcinoma; Hepatocellular neoplasia; Hepatocyte growth factor; Preneoplasia; TGT RII; Transglutaminase; Ubiquitin

Indexed keywords

CYTOKERATIN; GAMMA GLUTAMYLTRANSFERASE; GRISEOFULVIN; MESSENGER RNA; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SCATTER FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; LIVER CELL CARCINOMA; LIVER HYPERPLASIA; LIVER TOXICITY; MALE; MESSENGER RNA SYNTHESIS; MOUSE; NONHUMAN; ONCOGENE C FOS; ONCOGENE C MYC; PRIORITY JOURNAL; TUMOR PROMOTION;

EID: 0032816783     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(99)00022-4     Document Type: Article

References (42)

1. Tazawa J., Irie T., French S.W. Mallory body formation runs parallel to γ-glutamyl transferase induction in hepatocytes of griseofulvin-fed mice. Hepatology. 3:1983;989-1001.
2. Yuan Q.X., Marceau N., French B.A., Fu P., French S.W. Mallory body induction in drug-primed mouse liver. Hepatology. 24:1996;603-612.
3. Nagao Y., French B.A., Cai Y., French S.W., Wan Y.J.Y. Inhibition of PPARα/RXRα mediated direct hyperplasia pathways during griseofulvin induced hepatocarcinogenesis. J. Cell. Biochem. Microbiol. Mol. Genet. 69:1998;189-200.
4. Inagaki M., Moustakas A., Lin H.Y., Lodish H.F., Carr I. Growth inhibition by transforming growth factor β (TGFβ) type I is restored in TGF-β resistant hepatoma cells after expression of TGF-β receptor type II cDNA. Proc. Natl. Acad. Sci. USA. 90:1993;5359-5363.
5. Millis J.J., Jirtle R.L., Boyer I.J. Mechanism of liver tumor promotion. Jirtle R.L. Liver Regeneration and Carcinogenesis, Molecular and Cellular Mechanism. 1995;199-226 Academic Press, San Diego.
6. Chiari R.S., Price D.T., Sue S.R., Meyers W.C., Jirtle R.L. Down-regulation of transforming growth factor β-receptor type I,II, and III during liver regeneration. Am. J. Surg. 169:1995;126-132.
7. Kemler R., Brulet P., Schnebelen M.T., Gaillard J., Jacob F. Reactivity of monoclonal antibodies against intermediate filament proteins during embryonic development. J. Embryol. Exp. Morphol. 64:1981;45-60.
8. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
9. Alitalo K., Schwab M., Lin C.C., Varmus H.E., Bishop J.M. Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a colon carcinoma. Proc. Natl. Acad. Sci. USA. 80:1983;1707-1711.
10. Ryder K., Nathans D. Induction of protooncogene c-jun by serum growth factors. Proc. Natl. Acad. Sci. USA. 85:1988;8464-8467.
11. Taube R. Expression and function of growth-induced genes during liver regeneration. Jirtle R.L. Liver Regeneration and Carcinogenesis. Molecular and Cellular Mechanism. 1995;71-98 Academic Press, San Diego.
12. Zatloukal K., Spurej G., Rainer I., Lackinger E., Denk H. Fate of Mallory body-containing hepatocytes: disappearance of Mallory bodies and restoration of the hepatic intermediate filament cytoskeleton after the drug withdrawal in the griseofulvin-treated mouse. Hepatology. 11:1990;652-661.
13. Kaczmarek L. Protooncogene expression during the cell cycle. Lab. Invest. 54:1986;356-376.
14. Bishop J.M. The molecular genetics of cancer. Science. 235:1986;305-311.
15. Shiota G., Wang T.C., Nakamura T., Schmidt E.V. Hepatocyte growth factor in transgenic mice: effect on hepatocyte growth, liver regeneration and gene expression. Hepatology. 19:1994;962-972.
16. Corral M., Paris B., Guguen-Guillouzo C., Corcos D., Kruh J., Defer N. Increased expression of the N-myc gene during normal and neoplastic rat liver growth. Exp. Cell. Res. 174:1988;107-115.
17. Ryseck P.P., Hirai S.I., Yaniv M., Bravo R. Transcriptional activation of c-jun during the G0/G1 transition in mouse fibroblast. Nature. 334:1988;535-537.
18. Hilberg F., Aguzzi A., Howells N., Wagner E.F. c-Jun is essential for normal mouse development and hepatogenesis. Nature. 365:1993;179-181.
19. Nagao Y., Yuan Q.X., Wan Y.J.Y., French B.A., French S.W. Pathogenesis of Mallory body formation: studies using the drug-primed mouse model. Hepatol. Res. 13:1998;42-54.
20. Gak E., Taylor W.G., Chan A.M.L., Rubin J.S. Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity. FEBS. Lett. 311:1992;17-21.
21. Miyazawa K., Shimomura T., Kitamura A., Kondo J., Morimoto Y., Kitamura N. Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. J. Biol. Chem. 286:1993;10024-10028.
22. Okajima A., Miyazawa K., Naitoh Y., Inoue K., Kitamura N. Induction of hepatocyte growth factor activator messenger RNA in the liver following tissue injury and acute inflammation. Hepatology. 25:1997;97-102.
23. Miyazawa K., Shimomura T., Kitamura N. Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. J. Biol. Chem. 271:1996;3615-3618.
24. Mars W.M., Zargenar R., Michalopoulos G.K. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am. J. Pathol. 143:1993;949-958.
25. Michalopoulos G.K. Hepatocyte growth factor (HGF) and its receptor (Met) in liver regeneration, neoplasia, and disease in liver regeneration. Jirtle R.L. Liver Regeneration and Carcinogenesis, Molecular and Cellular Mechanism. 1995;27-49 Academic Press, San Diegoy.
26. Tajima H., Matsumoto K., Nakamura T. Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS. Lett. 291:1991;229-232.
27. Santoni-Rugiu E., Preisegger K.H., Kiss A., Schmidt E.V., Thorgeirsson S.S. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Hepatology. 22:1995;219.
28. Katsuma Y., Marceau N., Ohta M., French S.W. Cytokeratin intermediate filaments of rat hepatocytes: different cytoskeletal domains and their three dimensional structure. Hepatology. 8:1988;559-568.
29. Cadrin M, Kawahara H, Ohta M, Katsuma Y, Marceau N, and French SW. Mallory bodies in hepatomas and hyperplastic nodules: In vivo and in vitro studies. In: Mouse liver carcinogenesis: mechanism and species comparisons. Progr Clin Biol Res 1990; 331: 231-248.
30. Cadrin M., Anderson N.M., Aasheim L.H., Kawahara H., Franks D.J., French S.W. Modifications in cytokeratin and actin in cultured liver cells derived from griseofulvin-fed mice. Lab. Invest. 72:1995;453-460.
31. Kachi K., Wong P.T.T., French S.W. Molecular structural changes in Mallory body protein in human and mouse livers: an infrared spectroscopy study. Exp. Mol. Pathol. 59:1993;197-210.
32. Cadrin M., French S.W., Wong P.T.T. Alteration in molecular structure of cytoskeletal proteins in griseofulvin treated mouse liver:suppressive tuning infrared spectroscopy study. Exp. Mol. Pathol. 55:1991;170-179.
33. Tyner A.L., Fuchs E. Evidence for post transcriptional regulation of the keratins expressed during hyperproliferation and malignant transformation in human epidermis. J. Cell Biol. 103:1986;1945-1955.
34. Jensen K., Gluud C. The Mallory body: morphological, clinical and experimental studies (part 1 of a literature survey). Hepatology. 20:1994;1061-1077.
35. Nakanuma Y., Ohta G. Expression of Mallory bodies in hepatocellular carcinoma in man and its significance. Cancer. 57:1986;81-86.
36. Pankov R., Umezawa A., Maki R., Der C.J., Hauser C.A., Oshima R.G. Oncogene activation of human keratin 18 transcription via the RAS signal transduction pathway. Proc. Natl. Acad. Sci. USA. 91:1994;873-877.
37. Meierhenny E.F., Ruebner B., French S.W. Mallory body formation in hepatic nodules of mice ingesting dieldrin. Lab. Invest. 44:1981;392-396.
38. Meierhenry E.E., Ruebner B.H., French S.W. Mallory bodies in hepatic tumors of mice induced by dieldrin. Hepatology. 3:1983;90-95.
39. Roomi M.W., Yuan Q., Wang J., French S.W. Hepatic preneoplastic foci induction in drug primed mice treated with thioacetamide: role of GST-μ induction. FASEB. J. 12:1998;336.
40. Yuan Q.X., Marceau N., French B.A., French S.W. Heat shock in vivo induces Mallory body formation in drug primed mouse liver. Exp. Mol. Pathol. 63:1995;63-76.
41. Yuan Q., Nagao Y., Wan Y., Hu B., Gaal K., French B.A., French S.W. Mechanisms of Mallory body formation induced by okadaic acid in drug primed mice. Exp. Mol. Pathol. 65:1998;87-103.
42. Zhang-Gouillon Z.Q., Yuan Q.X., Hu B., Gaal K., Marceau N., French B.A., French S.W. Alcohol induces Mallory body formation in drug primed mice. Hepatology. 27:1998;116-122.